HDAC8 and neuroblastoma: In line with this, treatment of high-grade neuroblastoma cells with the selective HDAC8 inhibitor PCI-34051 induces cellular differentiation (Rettig et al. 2015) and the class IIb HDAC inhibitor tubastatin A interferes with lysosomal trafficking and cellular stress-response mechanisms such as autophagy, rendering tumor cells more susceptible to cytotoxic treatment (Oehme et al. 2013).